Overexpression of ubiquitin-specific protease 22 predicts poor survival in patients with early-stage non-small cell lung cancer

European Journal of Histochemistry

Volumn 56, Issue 4, 2012, Pages 289-294

  Ning, J ^a   Zhang, J ^a   Liu, W ^a   Lang, Y ^a   Xue, Y ^a   Xu, S ^a  

^a HARBIN MEDICAL UNIVERSITY   (China)

Author keywords

Non small cell lung cancer; Prognosis; Ubiquitin specific protease 22

Indexed keywords

EID: 84880632246     PISSN: 1121760X     EISSN: None     Source Type: Journal    
DOI: 10.4081/ejh.2012.e46     Document Type: Article

References (24)

1. Jemal A, Bray F, Center MM, Ferlay J, Ward E, Forman D.Global cancer statistics. Ca-Cancer J Clin 2011;61:69-90
2. Herbst RS, Heymach JV, Lippman SM. Lung cancer. New Engl J Med 2008;359: 1367-80.
3. Hung JJ, Hsu WH, Hsieh CC, Huang BS, Huang MH, Liu JS, et al. Post-recurrence survival in completely resected stage I non-small cell lung cancer with local recur-rence. Thorax 2009;64:192-6.
4. Hung JJ, Jeng WJ, Hsu WH, Wu KJ, Chou TY, Hsieh CC, et al. Prognostic factors of postrecurrence survival in completely resected stage I non-small cell lung cancer with distant metastasis. Thorax 2010;65: 241-5.
5. Arriagada R, Bergman B, Dunant A, Le Chevalier T, Pignon JP, Vansteenkiste J. Cisplatin-based adjuvant chemotherapy in patients with completely resected non-small-cell lung cancer. New Engl J Med 2004;350:351-60.
6. Winton T, Livingston R, Johnson D, Rigas J, Johnston M, Butts C,et al. Vinorelbine plus cisplatin vs observation in resected non-small-cell lung cancer. New Engl J Med 2005;352:2589-97.
7. Douillard JY, Rosell R, De Lena M, Car-pagnano F, Ramlau R, Gonzales-Larriba JL, et al. Adjuvant vinorelbine plus cisplatin versus observation in patients with com-pletely resected stage IB-IIIA non-small-cell lung cancer (Adjuvant Navelbine International Trialist Association [ANITA]): a randomised controlled trial. Lancet Oncol 2006;7:719-27.
8. Pignon JP, Tribodet H, Scagliotti GV, Douillard JY, Shepherd FA, Stephens RJ, et al. Lung adjuvant cisplatin evaluation: a pooled analysis by the LACE Collaborative Group. J Clin Oncol 2008;26:3552-9.
9. Strauss GM, Herndon JE II, Maddaus MA, Johnstone DW, Johnson EA, Harpole DH, et al. Adjuvant paclitaxel plus carboplatin compared with observation in stage IB non-small-cell lung cancer: CALGB 9633 with the cancer and leukemia group b, radiation therapy oncology group, and north central cancer treatment group study groups. J Clin Oncol 2008;26:5043-51.
10. Glinsky GV, Berezovska O, Glinskii AB. Microarray analysis identifies a death-from-cancer signature predicting therapy failure in patients with multiple types of cancer. J Clin Invest 2005;115:1503-21.
11. Berger SL. The complex language of chro-matin regulation during transcription. Nature 2007;447:407-12.
12. Lee KK, Florens L, Swanson SK, Washburn MP, Workman JL. The deubiquitylation activity of Ubp8 is dependent upon Sgf11 and its association with the SAGA com-plex. Mol Cell Biol 2005;25:1173-82.
13. Berezovska OP, Glinskii AB, Yang Z, Li XM, Hoffman RM, Glinsky GV. Essential role for activation of the Polycomb group (PcG) protein chromatin silencing pathway in metastatic prostate cancer. Cell Cycle 2006;5:1886-901.
14. Zhang XY, Pfeiffer HK, Thorne AW, McMahon SB. USP22, an hSAGA subunit and potential cancer stem cell marker, reverses the polycomb-catalyzed ubiquity-lation of histone H2A. Cell Cycle 2008; 7:1522-4.
15. Liu YL, Jiang SX, Yang YM, Xu H, Liu JL, Wang XS. USP22 acts as an oncogene by the activation of BMI-1-mediated INK4a/ ARF pathway and Akt pathway. Cell Biochem Biophys 2012;62:229-35.
16. Lee HJ, Kim MS, Shin JM, Park TJ, Chung HM, Baek KH. The expression patterns of deubiquitinating enzymes, USP22 and Usp22. Gene Expr Patterns 2006;6:277-84.
17. Liu YL, Yang YM, Xu H, Dong XS. Increased expression of ubiquitin-specific protease 22 can promote cancer progression and predict therapy failure in human colorectal cancer. J Gastroenterol Hepatol 2010;25: 1800-5.
18. Liu YL, Yang YM, Xu H, Dong XS. Aberrant expression of USP22 is associated with liver metastasis and poor prognosis of col-orectal cancer. J Surg Oncol 2011;103:283-9.
19. Zhang Y, Yao L, Zhang X, Ji H, Wang L, Sun S, et al. Elevated expression of USP22 in correlation with poor prognosis in patients with invasive breast cancer. J Cancer Res Clin 2011;137:1245-53.
20. Yang DD, Cui BB, Sun LY, Zheng HQ, Huang Q, Tong JX, et al. The co-expression of USP22 and BMI-1 may promote cancer progression and predict therapy failure in gastric carcinoma. Cell Biochem Biophys 2011;61:703-10.
21. Zhang XY, Varthi M, Sykes SM, Phillips C, Warzecha C, Zhu W, et al. The putative cancer stem cell marker USP22 is a sub-unit of the human SAGA complex required for activated transcription and cell-cycle progression. Mol Cell 2008;29:102-11.
22. Brambilla E, Travis WD, Colby TV, Corrin B, Shimosato Y. The new World Health Organization classification of lung tumours. Eur Respir J 2001;18:1059-68.
23. Mountain CF. Revisions in the internation-al system for staging lung cancer. Chest 1997;111:1710-7.
24. Livak KJ, Schmittgen TD. Analysis of rela-tive gene expression data using real-time quantitative PCR and the 2(-Delta Delta C(T)) method. Methods 2001;25:402-8.